新着情報News
【PharmaBlock (Nanjing) 】Application of Halogen Bond in Drug Discovery
- 2023/10/30
- サプライヤニュース
Introduction
Halogen bond (XB) is a highly directional and specific interaction driven by the σ-hole, a positively charged region on the hind side of X along the R−X bond axis that is caused by an anisotropy of electron density on the halogen (Figure 1a)1. Halogen bond is formed between a covalently bonded halogen atom (XB donor) and a nucleophile (i.e., Lewis base; XB acceptor) (Figure 1b). In general, heavy halogens, such as -Cl, -Br and -I, can form halogen bonds while fluorine cannot2.
Figure1a) Figure1b)
Figure 1: 1a) The anisotropy of the electron density on the Halogen. The positive surface potential (including the σ-hole on the halogen) is colored in red, and the negative surface potential is colored in light blue. 1b) Typical Halogen bonds: one covalently bonded halogen atom and a nucleophile. R-X... acceptor angle is close to 180o.
In protein−ligand environments, halogen bonds can be formed between a halogenated ligand and any accessible Lewis base in the binding pocket, such as the backbone carbonyl oxygen, hydroxyls in serine, threonine, and tyrosine, carboxylate groups in aspartate and glutamate, sulfur in cysteine and methionine, nitrogen in histidine, and the π surface of phenylalanine, tyrosine, histidine, and tryptophan1. One typical example is halogen atoms getting involved in the hinge region binding instead of the canonical hinge binders (Figure 2)1.
Figure2 a)
Figure2 b)
Figure 2: 2a) Kinase Hinge binding through two chlorine atoms with the backbone carbonyl oxygens; 2b) Kinase Canonical Hinge binding by Hydrogen bonds.Halogen bond has attracted a lot of attention in drug discovery for hit-to-lead-to-candidate optimization aiming at improving drug-target binding affinity over the past twenty years. The improvement of potency ranges from several folds (Figure 3a)3 to many folds (Figure 3b)4.
Figure3.Halogen bond can increase the potency several folds
Figure 4. Halogen bond can increase the potency many folds
Synthesis of Aryl Halides
1.Substitution of diazonium groups in aromatic compounds by halo.
Substitution of diazonium groups in aromatic compounds by halo or cyano groups in the presence of cuprous salts (Sandmeyer reaction), copper powder and hydrochloric or hydrobromic acid (Gattermann reaction) or cupric salts (Körner-Contardi reaction).
Formation of diazonium fluoroborates by diazotization of aromatic amines in the presence of fluoroborates, followed by their thermal decomposition to aryl fluorides (Balz-Schiemann reaction):
2.Electrophilic addition of aromatic compounds
RSC Advances, 2022, 12, 7115 - 71193.Reaction of aryl lithium and active halide (Br2, CBr4, 1,2-dibromotetrafluoroethane, I2, hexachloroethane, NFSI, etc).
4.Bromination of phenols
Organic Syntheses, Coll. 1973,5,142 ; 1969,49, 65.Halogen exchange reaction
Journal of the American Chemical Society, 1959, 81, 3984-9
6.Photoassisted Cristol-Firth-Hunsdiecker reaction
Journal of Organic Chemistry, 1979, 44, 3405-6
7.Decarboxylation halogenation
J. Am. Chem. Soc. 2017, 139, 11527−11536
J. Name., 2013, 00, 1-3
J. Org. Chem. 2009, 74, 8874–8877
Organic Letters, 2005,7, 4753-47568.Ortho-iodination reaction of benzoic acid derivatives via directed ortho-palladation followed by metal–iodine exchange
US2013/5705
Chemistry - A European Journal, 2009, 15, .5956 - 5968
9.Halodeboronation of aryl boronic acids
J. Org. Chem. 2004, 69, 566-569
US20210130369
Organic Letters,2019, 21, 2488-2492
- Ligand-free and base-free
- functional group tolerable
- Gram-scale reaction
Tetrahedron Letters, 2021, 64, 152738
10.Using aliphatic brominated compounds as starting materials
Bioorganic & Medicinal Chemistry, 2021, 52, 116522
Building Blocks Containing Halogen
PharmaBlock has conducted a systematic study of clinical and preclinical drug molecules, and our chemists continue to pay attention to the latest research, design and synthesize a large number of halogenated organic compounds , which can be used to explore structure-activity relationship (SAR) and structure-property relationship (SPR). We offer more than 10000 unique heterocyclic building blocks, ranging from grams to kilograms, most of which are in stock (Figure 5).
Figure 5. Representative building blocks containing halogen bonds at PharmaBlock
✎ 参 考 文 献
[1] Principles and Applications of Halogen Bonding in Medicinal Chemistry and Chemical Biology. Rainer Wilcken et al. J. Med. Chem. 2013, 56, 1363−1388.
[2] Halogen Bond: Its Role beyond Drug−Target Binding Affinity for Drug Discovery and Development. Zhijian Xu et al. J. Chem. Inf. Model. 2014, 54, 69−78.
[3] Design and Synthesis of highly Potent and Selective (2-arylcarbamoyl-phenoxy)-acetic acid Inhibitors of Aldose Reductase for Treatment of Chronic Diabetic Complications. Michael C. Van Zandt et al. Bioorg. Med. Chem., 2004, 12, 5661-5675.
[4] “Magic Chloro”: Profound Effects of the Chlorine Atom in Drug Discovery. Debora Chiodi and Yoshihiro Ishihara. J. Med. Chem. 2023, 66, 8, 5305-5331.
[5] DABCO as a practical catalyst for aromatic halogenation with N-halosuccinimides. Xu, Haiyan et al. RSC Advances, 2022, 12, 7115 – 7119.
[6] Synthesis of 2-BROMONAPHTHALENE, Organic Syntheses, Coll. 1973,5,142 ; 1969,49, 6
[7] Nitrogen mustard analogs of antimalarial drugs. Peck, Richard M. et al. Journal of the American Chemical Society, 1959, 81, 3984-9.
[8] Photoassisted Cristol-Firth-Hunsdiecker reaction. Meyers, A. I.; Fleming, Michael P. Journal of Organic Chemistry, 1979, 44, 3405-6.
[9] Transition-metal-free decarboxylative iodination: New routes for decarboxylative oxidative cross-couplings. Perry, Gregory J. P. et al. Journal of the American Chemical Society, 2017, 139, 11527-11536.
[10] Halogen-Bonding in a New Family of tris(haloanilato)metallate(III) Magnetic Molecular Building Blocks, J. Name., 2013, 00, 1-3
[11] Bromodecarboxylation of Quinoline Salicylic Acids: Increasing the Diversity of Accessible Substituted Quinolines. Janz, Kristin; Kaila, Neelu. Journal of Organic Chemistry, 2009, 74, 8874-8877.
[12] Pyrazolo[1,5-a]pyridines as p38 Kinase Inhibitors. Stevens, Kirk L. et al. Organic Letters, 2005, 7, 4753-4756
[13] Total Synthesis of the Aspercyclides. Pospisil, Jiri; Mueller, Christoph; Fuerstner, Alois. Chemistry - A European Journal, 2009, 15, 5956-5968.
[14] Facile synthesis of 2-bromo-3-fluorobenzonitrile: An application and study of the halodeboronation of arylboronic acids. Szumigala, Ronald H. Jr. et al. Journal of Organic Chemistry, 2004, 69, 566-569
[15] US20210130369, 2021.
[16] Mechanism of Cu-Catalyzed Aryl Boronic Acid Halodeboronation Using Electrophilic Halogen: Development of a Base-Catalyzed Iododeboronation for Radiolabeling Applications. Molloy, John J. et al. Organic Letters, 2019, 21, 2488-2492.
[17] Direct bromodeboronation of arylboronic acids with CuBr2 in water. Tang, Yan-Ling et al. Tetrahedron Letters, 2021, 64, 152738.
[18] AMPK inhibitor BML-275 induces neuroprotection through decreasing cyt c and AIF expression after transient brain ischemia. Hu, Yue; Dong, Yao-Dong et al. Bioorganic & Medicinal Chemistry, 2021, 52, 116522.
PharmaBlock (Nanjing) (ファーマブロック)社について
- 設立
- 2008年
- 社員数
- 2600名
- 本社所在地
- 中国
- URL
- https://www.pharmablock.com/
PharmaBlock Sciences (Nanjing), Inc.は研究開発を通して革新的な化合物とサービスを提供しております。コアビジネスはスキャフォールド、Building Block、プロセス開発と重要中間体や出発原料の製造です。ビルディングブロックのスケールアップが可能です。
PharmaBlockは構造のデザイン、ラボスケールでのBuilding Blockの合成などのビジネスで急速に認知度が高まっております。2016年には、Shandong Diai Biotechnology Co., Ltd. をパイロットプラント及び製造サイトとして買収し、重要中間体や出発原料等のスケールアップ・製造を行っております。PharmaBlockはお客様への包括的かつ長期的なサービスに取組んでおります。
特徴
- グラム~トンスケールまで自社内で対応可能な数少ないCDMO
- フローケミストリー対応可能
- non-GMP/GMP対応可能
- カタログ品からのスケールアップ対応可能